Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season.

Flannery B, Kondor RJG, Chung JR, Gaglani M, Reis M, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Kim SS, Blanton L, Kniss K, Budd AP, Brammer L, Stark TJ, Barnes JR, Wentworth DE, Fry AM, Patel M.

J Infect Dis. 2020 Jan 1;221(1):8-15. doi: 10.1093/infdis/jiz543.

PMID:
31665373
2.

Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years.

Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, Smith KJ.

J Community Health. 2019 Aug 10. doi: 10.1007/s10900-019-00716-8. [Epub ahead of print]

PMID:
31401746
3.

Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses.

Carlock MA, Ingram JG, Clutter EF, Cecil NC, Ramgopal M, Zimmerman RK, Warren W, Kleanthous H, Ross TM.

Hum Vaccin Immunother. 2019;15(9):2030-2043. doi: 10.1080/21645515.2019.1642056. Epub 2019 Aug 8.

4.

Determination of Eligibility for Influenza Research: A Clinical Informatics Approach.

Silveira FP, Saul M, Nowalk MP, Saul S, Sax TM, Eng H, Zimmerman RK, Balasubramani GK.

Open Forum Infect Dis. 2019 Jun 10;6(6):ofz231. doi: 10.1093/ofid/ofz231. eCollection 2019 Jun.

5.

Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S.

Nowalk MP, Wateska AR, Lin CJ, Schaffner W, Harrison LH, Zimmerman RK, Smith KJ.

J Natl Med Assoc. 2019 Jun 3. pii: S0027-9684(18)30252-9. doi: 10.1016/j.jnma.2019.04.011. [Epub ahead of print]

PMID:
31171344
6.

Exploring the potential public health benefits of universal influenza vaccine.

DePasse JV, Nowalk MP, Smith KJ, Raviotta JM, Shim E, Zimmerman RK, Brown ST.

Hum Vaccin Immunother. 2019;15(12):2919-2926. doi: 10.1080/21645515.2019.1619406. Epub 2019 Jun 18.

PMID:
31091166
7.

Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.

Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, Smith KJ.

Vaccine. 2019 Mar 28;37(14):2026-2033. doi: 10.1016/j.vaccine.2019.01.002. Epub 2019 Mar 4.

PMID:
30846259
8.

Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis.

Smith KJ, France G, Nowalk MP, Raviotta JM, DePasse J, Wateska A, Shim E, Zimmerman RK.

Am J Prev Med. 2019 Apr;56(4):e135-e141. doi: 10.1016/j.amepre.2018.11.015. Epub 2019 Feb 14.

PMID:
30772149
9.

Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019.

Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Foust A, Sessions W, Berman L, Garten RJ, Barnes JR, Wentworth DE, Fry AM, Patel MM, Flannery B.

MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):135-139. doi: 10.15585/mmwr.mm6806a2.

10.

Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season.

Rolfes MA, Flannery B, Chung JR, O'Halloran A, Garg S, Belongia EA, Gaglani M, Zimmerman RK, Jackson ML, Monto AS, Alden NB, Anderson E, Bennett NM, Billing L, Eckel S, Kirley PD, Lynfield R, Monroe ML, Spencer M, Spina N, Talbot HK, Thomas A, Torres SM, Yousey-Hindes K, Singleton JA, Patel M, Reed C, Fry AM; US Influenza Vaccine Effectiveness (Flu VE) Network, the Influenza Hospitalization Surveillance Network, and the Assessment Branch, Immunization Services Division, Centers for Disease Control and Prevention .

Clin Infect Dis. 2019 Nov 13;69(11):1845-1853. doi: 10.1093/cid/ciz075.

PMID:
30715278
11.

Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons.

Havers FP, Hicks LA, Chung JR, Gaglani M, Murthy K, Zimmerman RK, Jackson LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA, Flannery B, Fry AM.

JAMA Netw Open. 2018 Jun 1;1(2):e180243. doi: 10.1001/jamanetworkopen.2018.0243.

12.

An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.

Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, Smith KJ.

Hum Vaccin Immunother. 2019;15(4):863-872. doi: 10.1080/21645515.2018.1564439. Epub 2019 Feb 20.

PMID:
30633706
13.

Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults.

France G, Wateska AR, Nowalk MP, DePasse J, Raviotta JM, Shim E, Zimmerman RK, Smith KJ.

Innov Aging. 2018 Dec 14;2(3):igy035. doi: 10.1093/geroni/igy035. eCollection 2018 Sep.

14.

Inflammatory Mediator Expression Associated With Antibody Response Induced by Live Attenuated vs Inactivated Influenza Virus Vaccine in Children.

Martin JM, Avula R, Nowalk MP, Lin CJ, Horne WT, Chandran UR, Nagg JP, Zimmerman RK, Cole KS, Alcorn JF.

Open Forum Infect Dis. 2018 Oct 24;5(11):ofy277. doi: 10.1093/ofid/ofy277. eCollection 2018 Nov.

15.

Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016.

Shang M, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Fry AM, Flannery B.

Vaccine. 2018 Dec 18;36(52):8047-8053. doi: 10.1016/j.vaccine.2018.10.093. Epub 2018 Nov 9.

PMID:
30420119
16.

Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011-12-2015-16.

Appiah GD, Chung JR, Flannery B, Havers FP, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Gaglani M, Murthy K, Jackson LA, Jackson ML, McLean HQ, Belongia EA, Fry AM.

Influenza Other Respir Viruses. 2019 Mar;13(2):133-137. doi: 10.1111/irv.12616. Epub 2018 Dec 19.

17.

Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011-2017.

Havers FP, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, Fry AM, Flannery B.

Clin Infect Dis. 2019 May 2;68(10):1616-1622. doi: 10.1093/cid/ciy780.

18.

Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season.

Flannery B, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Rolfes MA, Spencer S, Fry AM; US Flu VE Investigators .

Clin Infect Dis. 2019 May 17;68(11):1798-1806. doi: 10.1093/cid/ciy775.

19.

Does influenza vaccination status change physician ordering patterns for respiratory viral panels? Inspection for selection bias.

Balasubramani GK, Saul S, Nowalk MP, Middleton DB, Ferdinands JM, Zimmerman RK.

Hum Vaccin Immunother. 2019;15(1):91-96. doi: 10.1080/21645515.2018.1514226. Epub 2018 Sep 19.

20.

Influenza Vaccine Intention After a Medically Attended Acute Respiratory Infection.

Nowalk MP, Balasubramani GK, Zimmerman RK, Bear TM, Sax T, Eng H, Susick M, Ford SE.

Health Promot Pract. 2019 Jul;20(4):539-552. doi: 10.1177/1524839918782137. Epub 2018 Jul 13.

21.

A Novel Representation of Vaccine Efficacy Trial Datasets for Use in Computer Simulation of Vaccination Policy.

Tajgardoon M, Wagner MM, Visweswara S, Zimmerman RK.

AMIA Jt Summits Transl Sci Proc. 2018 May 18;2017:389-398. eCollection 2018.

22.

Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.

Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman L, Barnes JR, Spencer S, Fry AM.

MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):180-185. doi: 10.15585/mmwr.mm6706a2.

23.

Influenza vaccine effectiveness in older adults compared with younger adults over five seasons.

Russell K, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Flannery B.

Vaccine. 2018 Feb 28;36(10):1272-1278. doi: 10.1016/j.vaccine.2018.01.045.

24.

Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.

Wateska AR, Nowalk MP, Zimmerman RK, Smith KJ, Lin CJ.

BMC Infect Dis. 2018 Jan 25;18(1):52. doi: 10.1186/s12879-018-2967-2.

25.

Impact of seasonal influenza vaccination in the presence of vaccine interference.

Shim E, Smith KJ, Nowalk MP, Raviotta JM, Brown ST, DePasse J, Zimmerman RK.

Vaccine. 2018 Feb 1;36(6):853-858. doi: 10.1016/j.vaccine.2017.12.067. Epub 2018 Jan 9.

26.

Using the 4 Pillars to increase vaccination among high-risk adults: who benefits?

Nowalk MP, Moehling KK, Zhang S, Raviotta JM, Zimmerman RK, Lin CJ.

Am J Manag Care. 2017 Nov;23(11):651-655.

27.

The effect of frailty on HAI response to influenza vaccine among community-dwelling adults ≥ 50 years of age.

Moehling KK, Nowalk MP, Lin CJ, Bertolet M, Ross TM, Carter CE, Susick M, Saul SG, Kaynar AM, Bromberger JT, Zimmerman RK.

Hum Vaccin Immunother. 2018 Feb 1;14(2):361-367. doi: 10.1080/21645515.2017.1405883. Epub 2017 Dec 20.

28.

Differential gene expression elicited by children in response to the 2015-16 live attenuated versus inactivated influenza vaccine.

Cole KS, Martin JM, Horne WT, Lin CJ, Nowalk MP, Alcorn JF, Zimmerman RK.

Vaccine. 2017 Dec 14;35(49 Pt B):6893-6897. doi: 10.1016/j.vaccine.2017.09.019. Epub 2017 Nov 11.

29.

Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains.

Nuñez IA, Carlock MA, Allen JD, Owino SO, Moehling KK, Nowalk P, Susick M, Diagle K, Sweeney K, Mundle S, Vogel TU, Delagrave S, Ramgopal M, Zimmerman RK, Kleanthous H, Ross TM.

PLoS One. 2017 Nov 1;12(11):e0185666. doi: 10.1371/journal.pone.0185666. eCollection 2017.

30.

Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons-United States, 2011-2016.

Stewart RJ, Flannery B, Chung JR, Gaglani M, Reis M, Zimmerman RK, Nowalk MP, Jackson L, Jackson ML, Monto AS, Martin ET, Belongia EA, McLean HQ, Fry AM, Havers FP.

Clin Infect Dis. 2018 Mar 19;66(7):1035-1041. doi: 10.1093/cid/cix922.

31.

Using the 4 Pillars™ Practice Transformation Program to increase adolescent human papillomavirus, meningococcal, tetanus-diphtheria-pertussis and influenza vaccination.

Zimmerman RK, Raviotta JM, Nowalk MP, Moehling KK, Reis EC, Humiston SG, Lin CJ.

Vaccine. 2017 Oct 27;35(45):6180-6186. doi: 10.1016/j.vaccine.2017.09.039. Epub 2017 Sep 22.

32.

Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.

Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, Wateska A, France GS, Zimmerman RK.

Vaccine. 2017 Oct 9;35(42):5708-5713. doi: 10.1016/j.vaccine.2017.07.069. Epub 2017 Sep 7.

33.

Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.

Smith KJ, Nowalk MP, Lin CJ, Zimmerman RK.

Hum Vaccin Immunother. 2017 Oct 3;13(10):2207-2212. doi: 10.1080/21645515.2017.1356526.

34.

Prior-Season Vaccination and Risk of Influenza During the 2014-2015 Season in the United States.

Chung JR, Flannery B, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Petrie JG, Martin ET, Monto AS, McLean HQ, Belongia EA, Gaglani M, Fry AM.

J Infect Dis. 2017 Jul 15;216(2):284-285. doi: 10.1093/infdis/jix286. No abstract available.

35.

Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study.

DePasse JV, Nowalk MP, Smith KJ, Raviotta JM, Shim E, Zimmerman RK, Brown ST.

Vaccine. 2017 Jul 13;35(32):3974-3981. doi: 10.1016/j.vaccine.2017.05.093. Epub 2017 Jun 9.

36.

Reply to: Estimating the Full Value of High-Dose Influenza Vaccine.

Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, Zimmerman RK.

J Am Geriatr Soc. 2017 Sep;65(9):2111-2112. doi: 10.1111/jgs.14976. Epub 2017 Jun 6. No abstract available.

37.

Potential Consequences of Not Using Live Attenuated Influenza Vaccine.

Smith KJ, Nowalk MP, Wateska A, Brown ST, DePasse JV, Raviotta JM, Shim E, Zimmerman RK.

Am J Prev Med. 2017 Oct;53(4):500-503. doi: 10.1016/j.amepre.2017.02.019. Epub 2017 Apr 18.

38.

Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study.

DePasse JV, Smith KJ, Raviotta JM, Shim E, Nowalk MP, Zimmerman RK, Brown ST.

Am J Epidemiol. 2017 May 1;185(9):822-831. doi: 10.1093/aje/kww229.

39.

Are children's vitamin D levels and BMI associated with antibody titers produced in response to 2014-2015 influenza vaccine?

Lin CJ, Martin JM, Cole KS, Zimmerman RK, Susick M, Moehling KK, Levine MZ, Spencer S, Flannery B, Nowalk MP.

Hum Vaccin Immunother. 2017 Jul 3;13(7):1661-1665. doi: 10.1080/21645515.2017.1299837. Epub 2017 Mar 31.

40.

Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017.

Flannery B, Chung JR, Thaker SN, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Foust A, Sessions W, Berman L, Spencer S, Fry AM.

MMWR Morb Mortal Wkly Rep. 2017 Feb 17;66(6):167-171. doi: 10.15585/mmwr.mm6606a3.

41.

Using a Mixed Methods Approach to Examine Practice Characteristics Associated With Implementation of an Adult Immunization Intervention Using the 4 Pillars Practice Transformation Program.

Hawk M, Nowalk MP, Moehling KK, Pavlik V, Raviotta JM, Brown AE, Zimmerman RK, Ricci EM.

J Healthc Qual. 2017 May/Jun;39(3):153-167. doi: 10.1097/JHQ.0000000000000071.

42.

Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.

Smith KJ, Zimmerman RK, Nowalk MP, Lin CJ.

J Am Geriatr Soc. 2017 Apr;65(4):763-768. doi: 10.1111/jgs.14588. Epub 2016 Dec 26.

43.

Improving adolescent HPV vaccination in a randomized controlled cluster trial using the 4 Pillars™ practice Transformation Program.

Zimmerman RK, Moehling KK, Lin CJ, Zhang S, Raviotta JM, Reis EC, Humiston SG, Nowalk MP.

Vaccine. 2017 Jan 3;35(1):109-117. doi: 10.1016/j.vaccine.2016.11.018. Epub 2016 Nov 18.

44.

The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis.

Michaelidis CI, Fine MJ, Lin CJ, Linder JA, Nowalk MP, Shields RK, Zimmerman RK, Smith KJ.

BMC Infect Dis. 2016 Nov 8;16(1):655.

45.

Using the 4 pillars™ practice transformation program to increase adult influenza vaccination and reduce missed opportunities in a randomized cluster trial.

Lin CJ, Nowalk MP, Pavlik VN, Brown AE, Zhang S, Raviotta JM, Moehling KK, Hawk M, Ricci EM, Middleton DB, Patel S, South-Paul JE, Zimmerman RK.

BMC Infect Dis. 2016 Nov 3;16(1):623.

46.

Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.

Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, Zimmerman RK.

J Am Geriatr Soc. 2016 Oct;64(10):2126-2131. doi: 10.1111/jgs.14323. Epub 2016 Oct 6.

47.

Using the 4 Pillars Practice Transformation Program to Increase Pneumococcal Immunizations for Older Adults: A Cluster-Randomized Trial.

Zimmerman RK, Brown AE, Pavlik VN, Moehling KK, Raviotta JM, Lin CJ, Zhang S, Hawk M, Kyle S, Patel S, Ahmed F, Nowalk MP.

J Am Geriatr Soc. 2017 Jan;65(1):114-122. doi: 10.1111/jgs.14451. Epub 2016 Oct 18.

48.

2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type.

Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M, Murthy K, Fry AM, Flannery B; US Flu VE Investigators; U.S. Flu VE Investigators.

Clin Infect Dis. 2016 Dec 15;63(12):1564-1573. Epub 2016 Oct 4.

49.

The effect of perceived psychological stress on the immunogenicity of the quadrivalent human papillomavirus vaccine in males.

Wu RF, Zimmerman RK, Lin CJ.

Hum Vaccin Immunother. 2017 Mar 4;13(3):676-679. doi: 10.1080/21645515.2016.1236880. Epub 2016 Sep 28.

50.

Classification and Regression Tree (CART) analysis to predict influenza in primary care patients.

Zimmerman RK, Balasubramani GK, Nowalk MP, Eng H, Urbanski L, Jackson ML, Jackson LA, McLean HQ, Belongia EA, Monto AS, Malosh RE, Gaglani M, Clipper L, Flannery B, Wisniewski SR.

BMC Infect Dis. 2016 Sep 22;16(1):503.

Supplemental Content

Loading ...
Support Center